NEA Management Company, LLC
13F Reported Value
ⓘ$1.6B
Holdings
26
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
NEA Management Company, LLC disclosed 26 positions worth $1.6B in its Form 13F-HR for Q2 2026, led by $TRVI (Trevi Therapeutics, Inc.) at 15.5% of the equity portfolio, followed by $MBX and $GLUE. During the quarter the fund opened 1 new position and exited 1 — including a new stake in $KPTI and a full exit from $ACLX. The portfolio is most concentrated in Healthcare (95.4% of disclosed assets). All figures are sourced directly from NEA Management Company, LLC’s Form 13F-HR filing with the SEC under CIK 1512848.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$246.6M13,222,228 sh - —
Quality
$199.5M3,614,486 sh - 30.3#2,494
Quality
$186.2M7,692,298 sh - —
Quality
$179.0M1,710,561 sh - —
Quality
$164.6M7,392,301 sh - —
Quality
$150.7M24,471,264 sh - 7.4
Quality
$102.1M4,023,219 sh - 36.7
Quality
$72.6M12,867,769 sh - 75.2
Quality
$67.4M3,969,834 sh - 9.7
Quality
$57.7M1,058,570 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Trevi Therapeutics, Inc.$TRVI | — | $246.6M | 13,222,228 |
 MBX Biosciences, Inc.$MBX | — | $199.5M | 3,614,486 |
 Monte Rosa Therapeutics, Inc.$GLUE | 30.3#2,494 | $186.2M | 7,692,298 |
 Celcuity Inc.$CELC | — | $179.0M | 1,710,561 |
 SpyGlass Pharma, Inc.$SGP | — | $164.6M | 7,392,301 |
 Savara Inc$SVRA | — | $150.7M | 24,471,264 |
 Zenas BioPharma, Inc.$ZBIO | 7.4 | $102.1M | 4,023,219 |
 Coursera, Inc.$COUR | 36.7 | $72.6M | 12,867,769 |
 Aurinia Pharmaceuticals Inc.$AUPH | 75.2 | $67.4M | 3,969,834 |
 CRISPR Therapeutics AG$CRSP | 9.7 | $57.7M | 1,058,570 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of NEA Management Company, LLC's 26 positions.
Showing top 10 of 26 holdings.
Sector Allocation
Healthcare
$1.5B
Technology
$72.6M
Full Holdings — NEA Management Company, LLC (Q2 2026)
All 26 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $TRVI | Trevi Therapeutics, Inc. | $246.6M | 15.5% | +0% | — |
| 2 | $MBX | MBX Biosciences, Inc. | $199.5M | 12.6% | +0% | — |
| 3 | $GLUE | Monte Rosa Therapeutics, Inc. | $186.2M | 11.7% | +0% | 30.3 |
| 4 | $CELC | Celcuity Inc. | $179.0M | 11.3% | -25% | — |
| 5 | $SGP | SpyGlass Pharma, Inc. | $164.6M | 10.4% | +0% | — |
| 6 | $SVRA | Savara Inc | $150.7M | 9.5% | +0% | — |
| 7 | $ZBIO | Zenas BioPharma, Inc. | $102.1M | 6.4% | +0% | 7.4 |
| 8 | $COUR | Coursera, Inc. | $72.6M | 4.6% | +0% | 36.7 |
| 9 | $AUPH | Aurinia Pharmaceuticals Inc. | $67.4M | 4.2% | +0% | 75.2 |
| 10 | $CRSP | CRISPR Therapeutics AG | $57.7M | 3.6% | +0% | 9.7 |
| 11 |  $ORIC | Oric Pharmaceuticals, Inc. | $44.6M | 2.8% | +0% | — |
| 12 |  $PHAT | Phathom Pharmaceuticals, Inc. | $21.3M | 1.3% | +0% | 40.9 |
| 13 |  $KRRO | Korro Bio, Inc. | $17.1M | 1.1% | +0% | 14.1 |
| 14 |  $XFOR | X4 Pharmaceuticals, Inc | $15.1M | 0.9% | +0% | 28 |
| 15 |  $CSBR | CHAMPIONS ONCOLOGY, INC. | $10.6M | 0.7% | +0% | 26.5 |
| 16 |  $NKTX | Nkarta, Inc. | $10.1M | 0.6% | +0% | — |
| 17 |  $CVRX | CVRx, Inc. | $10.0M | 0.6% | -4% | 28.1 |
| 18 |  $BDTX | Black Diamond Therapeutics, Inc. | $8.2M | 0.5% | +0% | 37.2 |
| 19 |  $KPTI | Karyopharm Therapeutics Inc. | $5.6M | 0.3% | NEW | 15.1 |
| 20 |  $IVA | Inventiva S.A. | $5.5M | 0.3% | +0% | — |
| 21 |  $LONA | LeonaBio, Inc. | $4.3M | 0.3% | +0% | — |
| 22 |  $SNTI | Senti Biosciences Holdings, Inc. | $4.2M | 0.3% | +0% | — |
| 23 |  $MRKR | Marker Therapeutics, Inc. | $2.4M | 0.1% | +0% | — |
| 24 |  $OKUR | OnKure Therapeutics, Inc. | $2.2M | 0.1% | +0% | — |
| 25 |  $IMA | ImageneBio, Inc. | $295,030 | 0.0% | +0% | 6.6 |
| 26 |  $GOSS | Gossamer Bio, Inc. | $164,600 | 0.0% | +0% | 8.2 |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for NEA Management Company, LLC including:
Track NEA Management Company, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for NEA Management Company, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: NEA Management Company, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For NEA Management Company, LLC (SEC CIK: 1512848), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in NEA Management Company, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.